Details
Stereochemistry | RACEMIC |
Molecular Formula | C25H36N6O4S |
Molecular Weight | 516.656 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCOC1=CC=C(C=C1C2=NC(=O)C3=C(N2)C(CCC)=NN3C)S(=O)(=O)NCCC4CCCN4C
InChI
InChIKey=IYFNEFQTYQPVOC-UHFFFAOYSA-N
InChI=1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32)
Molecular Formula | C25H36N6O4S |
Molecular Weight | 516.656 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Udenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction. Udenafil inhibits the cyclic GMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of Cyclic GMP in the corpus cavernosum located around the penis. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. So the inhibition of phosphodiesterase type 5 (PDE5) by Udenafil enhances erectile function by increasing the amount of Cyclic GMP. Udenafil has proven to have high efficacy and a favorable safety profile for a broad spectrum of erectile dysfunction patients, which are comparable to those of other PDE5Is. Due to the clinical properties of relatively rapid onset and long duration of action, Udenafil may be a better option for erectile dysfunction treatment according to patient-specific sex-life patterns. Udenafil is as effective in the treatment of diabetes mellitus-associated erectile dysfunction as other PDE5Is. Recent data suggest that the concomitant use of anti-hypertensive drugs does not significantly affect the efficacy and safety profile. Also, due to its clinical properties, Udenafil can be a daily-dosing option for the treatment of erectile dysfunction, as suggested by its favorable efficacy and safety profile. Udenafil has been approved in South Korea and will be marketed under the brand name Zydena.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1827 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12510841 |
8.25 nM [IC50] |
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:42:41 UTC 2023
by
admin
on
Fri Dec 15 16:42:41 UTC 2023
|
Record UNII |
L5IB4XLY36
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2127
Created by
admin on Fri Dec 15 16:42:41 UTC 2023 , Edited by admin on Fri Dec 15 16:42:41 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/16/1807
Created by
admin on Fri Dec 15 16:42:41 UTC 2023 , Edited by admin on Fri Dec 15 16:42:41 UTC 2023
|
||
|
FDA ORPHAN DRUG |
449714
Created by
admin on Fri Dec 15 16:42:41 UTC 2023 , Edited by admin on Fri Dec 15 16:42:41 UTC 2023
|
||
|
WHO-ATC |
G04BE11
Created by
admin on Fri Dec 15 16:42:41 UTC 2023 , Edited by admin on Fri Dec 15 16:42:41 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C74086
Created by
admin on Fri Dec 15 16:42:41 UTC 2023 , Edited by admin on Fri Dec 15 16:42:41 UTC 2023
|
PRIMARY | |||
|
DB06267
Created by
admin on Fri Dec 15 16:42:41 UTC 2023 , Edited by admin on Fri Dec 15 16:42:41 UTC 2023
|
PRIMARY | |||
|
CHEMBL2103849
Created by
admin on Fri Dec 15 16:42:41 UTC 2023 , Edited by admin on Fri Dec 15 16:42:41 UTC 2023
|
PRIMARY | |||
|
XX-10
Created by
admin on Fri Dec 15 16:42:41 UTC 2023 , Edited by admin on Fri Dec 15 16:42:41 UTC 2023
|
PRIMARY | |||
|
135413547
Created by
admin on Fri Dec 15 16:42:41 UTC 2023 , Edited by admin on Fri Dec 15 16:42:41 UTC 2023
|
PRIMARY | |||
|
UDENAFIL
Created by
admin on Fri Dec 15 16:42:41 UTC 2023 , Edited by admin on Fri Dec 15 16:42:41 UTC 2023
|
PRIMARY | |||
|
8551
Created by
admin on Fri Dec 15 16:42:41 UTC 2023 , Edited by admin on Fri Dec 15 16:42:41 UTC 2023
|
PRIMARY | |||
|
L5IB4XLY36
Created by
admin on Fri Dec 15 16:42:41 UTC 2023 , Edited by admin on Fri Dec 15 16:42:41 UTC 2023
|
PRIMARY | |||
|
m11297
Created by
admin on Fri Dec 15 16:42:41 UTC 2023 , Edited by admin on Fri Dec 15 16:42:41 UTC 2023
|
PRIMARY | Merck Index | ||
|
268203-93-6
Created by
admin on Fri Dec 15 16:42:41 UTC 2023 , Edited by admin on Fri Dec 15 16:42:41 UTC 2023
|
PRIMARY | |||
|
100000124303
Created by
admin on Fri Dec 15 16:42:41 UTC 2023 , Edited by admin on Fri Dec 15 16:42:41 UTC 2023
|
PRIMARY | |||
|
DTXSID00870301
Created by
admin on Fri Dec 15 16:42:41 UTC 2023 , Edited by admin on Fri Dec 15 16:42:41 UTC 2023
|
PRIMARY | |||
|
C419664
Created by
admin on Fri Dec 15 16:42:41 UTC 2023 , Edited by admin on Fri Dec 15 16:42:41 UTC 2023
|
PRIMARY | |||
|
4141
Created by
admin on Fri Dec 15 16:42:41 UTC 2023 , Edited by admin on Fri Dec 15 16:42:41 UTC 2023
|
PRIMARY | |||
|
SUB32099
Created by
admin on Fri Dec 15 16:42:41 UTC 2023 , Edited by admin on Fri Dec 15 16:42:41 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ENANTIOMER -> RACEMATE | |||
|
ENANTIOMER -> RACEMATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |